Active Ingredient History

NOW
  • Now
Pazopanib (VOTRIENT) is an orally bioavailable multi-targeted tyrosine kinase receptor inhibitor. Pazopanib inhibits vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-α and -β, fibroblast growth factor receptor (FGFR) -1 and -3, cytokine receptor (Kit), interleukin-2 receptor inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In an vitro study, pazopanib exerted anti-tumor effect through mechanisms including the Raf-MAPK/ERK (MEK)-extracellular signal-regulated kinase (ERK) pathway. It has good oral exposure and inhibits angiogenesis and tumor growth in mice. Pazopanib (VOTRIENT) was developed by GlaxoSmithKline for the treatment of solid tumours and age-related macular degeneration. However, Novartis acquired all the rights to the drug from GlaxoSmithKline. Pazopanib (VOTRIENT) is indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma.   NCATS

  • SMILES: CN(c1ccc2c(C)n(C)nc2c1)c3ccnc(Nc4ccc(C)c(c4)S(=O)(=O)N)n3
  • InChIKey: CUIHSIWYWATEQL-UHFFFAOYSA-N
  • Mol. Mass: 437.53
  • ALogP: 3.14
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

Australia

$28.2539 - $56.9742

United States

$79.8913 - $113.8264
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

gw780604 | gw 780604 | gw-780604 | gw 78603 | gw786034 | gw 786034 | gw786034b | gw 786034b | gw-786034b | pazopanib | pazopanib hcl | pazopanib hydrochloride | pazopanibum | votrient

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue